Choice of replacement fluid dialysate anion in continuous renal replacement therapy

被引:12
|
作者
Macias, WL
机构
[1] INDIANA UNIV,SCH MED,INDIANAPOLIS,IN
[2] ELI LILLY & CO,LILLY LAB CLIN RES,INDIANAPOLIS,IN 46285
关键词
hemofiltration; hemodiafiltration; ARF; dialysis solutions; lactate; bicarbonate; citrate; acetate;
D O I
10.1016/S0272-6386(96)90075-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Normalization of acid-base balance in patients with acute renal failure (ARF) is a primary goal of continuous extracorporeal renal replacement therapy (CRRT). During CRRT, alkali administration, either in the replacement fluid or by diffusive uptake from the dialysate, must replace not only the bicarbonate lost in the buffering of endogenous acid production, but also the bicarbonate lost across the hemodiafilter. In most patients with ARF, a buffer concentration of approximately 30 to 35 mmol/L and an ultrafiltration rate (or dialysate flow rate) approaching or exceeding 1 L/hr can be expected to normalize the acid-base status within 1 to 2 days. In individuals with ARF and lactic acidemia, the buffer load may need to approach greater than or equal to 50 mmol/L to correct the associated metabolic acidemia. Acetate, bicarbonate, citrate, and lactate are the possible choices for bicarbonate or bicarbonate-equivalent administration during CRRT. Acetate- and lactate-based physiologic solutions have the advantage of being commercially available. Under normal conditions, acetate and lactate are metabolized rapidly to bicarbonate. Under conditions where the conversion pathways may be impaired, such as in severe hypoxic or shock states, excessive accumulation of these anions is possible. In the latter situation, the rate of anion conversion to bicarbonate may be slower than the rate of bicarbonate loss across the hemodiafilter, and a worsening of metabolic acidemia may occur. In addition, the administration of large amounts of lactate may result in increased urea generation. Bicarbonate has the major advantage of being the most physiologic anion. Unfortunately, the production of a commercially available bicarbonate-based physiologic solution is difficult because of the loss of bicarbonate from the solution or the formation of calcium and magnesium salts. The use of citrate as an anticoagulant obviates the need for additional alkali because citrate is metabolized to bicarbonate. Excessive citrate accumulation is rare, even in the setting of severe hepatic failure. (C) 1996 by the National Kidney Foundation, Inc.
引用
下载
收藏
页码:S15 / S20
页数:6
相关论文
共 50 条
  • [41] Continuous renal replacement therapy in poisoning
    Lundquist, Katja M. K.
    Hogberg, Lotte C. G.
    Bogevig, Soren
    CLINICAL TOXICOLOGY, 2023, 61 : 58 - 58
  • [42] Machines for continuous renal replacement therapy
    Ronco, C
    Brendolan, A
    Dan, M
    Piccinni, P
    Bellomo, R
    BLOOD PURIFICATION IN INTENSIVE CARE, 2001, 132 : 323 - 334
  • [43] Anticoagulation in continuous renal replacement therapy
    Rizo-Topete, Lilia
    Juncos, Luis Augusto
    GACETA MEDICA DE MEXICO, 2018, 154 : S61 - S71
  • [44] Machines for Continuous Renal Replacement Therapy
    Cruz, Dinna
    Bobek, Ilona
    Lentini, Paolo
    Soni, Sachin
    Chionh, Chang Yin
    Ronco, Claudio
    SEMINARS IN DIALYSIS, 2009, 22 (02) : 123 - 132
  • [45] Continuous renal replacement therapy principles
    Claure-Del Granado, Rolando
    Clark, William R.
    SEMINARS IN DIALYSIS, 2021, 34 (06) : 398 - 405
  • [46] The Origins of Continuous Renal Replacement Therapy
    Bartlett, Robert H.
    ASAIO JOURNAL, 2018, 64 (03) : 427 - 430
  • [47] Anticoagulation in continuous renal replacement therapy
    Hein, OV
    Kox, WJ
    Spies, C
    SEPSIS, KIDNEY AND MULTIPLE ORGAN DYSFUNCTION, 2004, 144 : 308 - 316
  • [48] Continuous renal replacement therapy in children
    Scott M. Sutherland
    Steven R. Alexander
    Pediatric Nephrology, 2012, 27 : 2007 - 2016
  • [49] Anticoagulation in continuous renal replacement therapy
    Abramson, S
    Niles, JL
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1999, 8 (06): : 701 - 707
  • [50] Dose in continuous renal replacement therapy
    Claure-Del Granado, Rolando
    GACETA MEDICA DE MEXICO, 2018, 154 : S40 - S47